1.
Chem Commun (Camb)
; 60(48): 6150-6153, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38804255
RESUMO
Iron-binding strategies in anticancer drug design target the key role of iron in cancer growth. The incorporation of a quinoline moiety in the design of tetrazolium-based prochelators facilitates their intracellular reduction/activation to iron-binding formazans. The new prochelators are antiproliferative at submicromolar levels, induce apoptosis and cell cycle arrest, and impact iron signaling in cancer cells.